company background image
AXGN logo

Axogen NasdaqCM:AXGN Stock Report

Last Price

US$12.64

Market Cap

US$556.3m

7D

-0.2%

1Y

115.0%

Updated

17 Nov, 2024

Data

Company Financials +

Axogen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Axogen
Historical stock prices
Current Share PriceUS$12.64
52 Week HighUS$15.90
52 Week LowUS$5.55
Beta1.13
11 Month Change-3.95%
3 Month Change3.10%
1 Year Change114.97%
33 Year Change29.51%
5 Year Change-21.83%
Change since IPO366.42%

Recent News & Updates

Recent updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Jul 29
A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Jun 12
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16
Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28
Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Sep 10
We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Aug 09
Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Jan 13
AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Is AxoGen (NASDAQ:AXGN) A Risky Investment?

Sep 10
Is AxoGen (NASDAQ:AXGN) A Risky Investment?

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

Aug 02

Shareholder Returns

AXGNUS Medical EquipmentUS Market
7D-0.2%-1.1%-2.1%
1Y115.0%22.8%30.2%

Return vs Industry: AXGN exceeded the US Medical Equipment industry which returned 22.8% over the past year.

Return vs Market: AXGN exceeded the US Market which returned 30.2% over the past year.

Price Volatility

Is AXGN's price volatile compared to industry and market?
AXGN volatility
AXGN Average Weekly Movement8.0%
Medical Equipment Industry Average Movement8.0%
Market Average Movement6.2%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: AXGN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AXGN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a427n/awww.axogeninc.com

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

Axogen, Inc. Fundamentals Summary

How do Axogen's earnings and revenue compare to its market cap?
AXGN fundamental statistics
Market capUS$556.26m
Earnings (TTM)-US$14.31m
Revenue (TTM)US$180.86m

3.1x

P/S Ratio

-38.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AXGN income statement (TTM)
RevenueUS$180.86m
Cost of RevenueUS$38.43m
Gross ProfitUS$142.43m
Other ExpensesUS$156.74m
Earnings-US$14.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin78.75%
Net Profit Margin-7.91%
Debt/Equity Ratio50.0%

How did AXGN perform over the long term?

See historical performance and comparison